ALB and cancer: Based on the accumulating evidence, inflammation-based models, such as the C-reactive protein/albumin ratio, albumin-to-globulin ratio (AGR), inflammation-based index (IBI), and neutrophil-to-lymphocyte ratio (NLR), and the platelet-to-lymphocyte ratio (PLR) have been developed to predict oncological outcomes in a variety of human cancers [6–9].